Aldose reductase gene polymorphisms and susceptibility to microvascular complications in Type 2 diabetes

Diabetic Medicine

Volumn 21, Issue 12, 2004, Pages 1325-1333

  Sivenius, Katariina ^a,b   Niskanen, L ^a   Voutilainen Kaunisto, R ^a   Laakso, M ^a   Uusitupa, M ^a  

^a KUOPIO UNIVERSITY HOSPITAL   (Finland)

^b UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

Aldose reductase; Gene; Microvascular complications; Polymorphism; Type 2 diabetes

Indexed keywords

ALDEHYDE REDUCTASE; POLYOL;

ADULT; ALLELE; ALR2 GENE; ARTICLE; CONTROLLED STUDY; DINUCLEOTIDE REPEAT; DNA SEQUENCE; FEMALE; GENE; GENE LINKAGE DISEQUILIBRIUM; GENETIC ANALYSIS; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GLUCOSE METABOLISM; HUMAN; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; MICROVASCULATURE; NON INSULIN DEPENDENT DIABETES MELLITUS; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RETINOPATHY; URINARY EXCRETION; VASCULAR DISEASE;

ALDEHYDE REDUCTASE; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 2; DIABETIC RETINOPATHY; FEMALE; GENETIC MARKERS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; STATISTICS, NONPARAMETRIC;

EID: 10244222747     PISSN: 07423071     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2004.01345.x     Document Type: Article

References (60)

1. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-986.
2. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
3. Ritz E, Stefanski A. Diabetic nephropathy in type II diabetes. Am J Kidney Dis 1996; 27: 167-194.
4. Seaquist ER, Goetz FC, Rich S, Barbosa J. Familial clustering of diabetic kidney disease. Evidence for genetic susceptibility to diabetic nephropathy. N Engl J Med 1989; 320: 1161-1165.
5. Canani LH, Gerchman F, Gross JL. Familial clustering of diabetic nephropathy in Brazilian type 2 diabetic patients. Diabetes 1999; 48: 909-913.
6. Graham A, Brown L, Hedge PJ, Gammack AJ, Markham AF. Structure of the human aldose reductase gene. J Biol Chem 1991; 266: 6872-6877.
7. Wang K, Bohren KM, Gabbay KH. Characterization of the human aldose reductase gene promoter. J Biol Chem 1993; 268: 16052-16058.
8. Greene DA, Lattimer SA, Sima AA. Sorbitol, phosphoinositides, and sodium-potassium-ATPase in the pathogenesis of diabetic complications. N Engl J Med 1987; 316: 599-606.
9. Nicolucci A, Carinci F, Cavaliere D, Scorpiglione N, Belfiglio M, Labbrozzi D et al. A meta-analysis of trials on aldose reductase inhibitors in diabetic peripheral neuropathy. The Italian Study Group. St Vincent Declaration. Diabet Med 1996; 13: 1017-1026.
10. Beyer-Mears A, Murray FT, Del Val M, Cruz E, Sciadini M. Reversal of proteinuria by sorbinil, an aldose reductase inhibitor in spontaneously diabetic (BB) rats. Pharmacology 1988; 36: 112-120.
11. Kador PF, Akagi Y, Takahashi Y, Ikebe H, Wyman M, Kinoshita JH. Prevention of retinal vessel changes associated with diabetic retinopathy in galactose-fed dogs by aldose reductase inhibitors. Arch Ophthalmol 1990; 108: 1301-1309.
12. Robison WG Jr, Nagata M, Laver N, Hohman TC, Kinoshita JH. Diabetic-like retinopathy in rats prevented with an aldose reductase inhibitor. Invest Ophthalmol Vis Sci 1989; 30: 2285-2292.
13. Mauer SM, Steffes MW, Azar S, Brown DM. Effects of sorbinil on glomerular structure and function in long-term-diabetic rats. Diabetes 1989; 38: 839-846.
14. Cameron NE, Leonard MB, Ross IS, Whiting PH. The effects of sorbinil on peripheral nerve conduction velocity, polyol concentrations and morphology in the streptozotocin-diabetic rat. Diabetologia 1986; 29: 168-174.
15. Li W, Khatami M, Rockey JH. The effects of glucose and an aldose reductase inhibitor on the sorbitol content and collagen synthesis of bovine retinal capillary pericytes in culture. Exp Eye Res 1985; 40: 439-444.
16. Hohman TC, Nishimura C, Robison WG Jr. Aldose reductase and polyol in cultured pericytes of human retinal capillaries. Exp Eye Res 1989; 48: 55-60.
17. Naruse K, Nakamura J, Hamada Y, Nakayama M, Chaya S, Komori T et al. Aldose reductase inhibition prevents glucose-induced apoptosis in cultured bovine retinal microvascular pericytes. Exp Eye Res 2000; 71: 309-315.
18. Miwa K, Nakamura J, Hamada Y. The role of polyol pathway in glucose-induced apoptosis of cultured retinal pericytes. Diabetes Res Clin Pract 2003; 60: 1-9.
19. Zager PG, Dorin RI, Shah VO, Kaplan DL, Mann PL, Frey HJ et al. Aldose reductase expression and prostaglandin E2 production are coordinately regulated in cultured rat mesangial cells. Metabolism 1993; 42: 269-276.
20. Shah VO, Scavini M, Nikolic J, Sun Y, Vai S, Griffith JK et al. Z-2 microsatellite allele is linked to increased expression of the aldose reductase gene in diabetic nephropathy. J Clin Endocrinol Metab 1998; 83: 2886-2891.
21. Nishimura C, Saito T, Ito T, Omori Y, Tanimoto T. High levels of erythrocyte aldose reductase and diabetic retinopathy in NIDDM patients. Diabetologia 1994; 37: 328-330.
22. Shah VO, Dorin RI, Sun Y, Braun M, Zager PG. Aldose reductase gene expression is increased in diabetic nephropathy. J Clin Endocrinol Metab 1997; 82: 2294-2298.
23. Takahashi Y, Tachikawa T, Ito T, Takayama S, Omori Y, Iwamoto Y. Erythrocyte aldose reductase protein: a clue to elucidate risk factors for diabetic neuropathies independent of glycemic control. Diabetes Res Clin Pract 1998; 42: 101-107.
24. Hasegawa G, Obayashi H, Kitamura A, Hashimoto M, Shigeta H, Nakamura N et al. Increased levels of aldose reductase in peripheral mononuclear cells from type 2 diabetic patients with microangiopathy. Diabetes Res Clin Pract 1999; 45: 9-14.
25. Shimizu H, Ohtani KI, Tsuchiya T, Sato N, Tanaka Y, Takahashi H et al. Aldose reductase mRNA expression is associated with rapid development of diabetic microangiopathy in Japanese Type 2 diabetic (T2DM) patients. Diabetes Nutr Metab 2000; 13: 75-79.
26. Imperatore G, Hanson RL, Pettitt DJ, Kobes S, Bennett PH, Knowler WC. Sib-pair linkage analysis for susceptibility genes for microvascular complications among Pima Indians with type 2 diabetes. Pima Diabetes Genes Group. Diabetes 1998; 47: 821-830.
27. n dinucleotide repeat polymorphic marker at the 5′ end of the aldose reductase gene is associated with early-onset diabetic retinopathy in NIDDM patients. Diabetes 1995; 44: 727-732.
28. Heesom AE, Hibberd ML, Millward A, Demaine AG. Polymorphism in the 5′-end of the aldose reductase gene is strongly associated with the development of diabetic nephropathy in type I diabetes. Diabetes 1997; 46: 287-291.
29. Moczulski DK, Scott L, Antonellis A, Rogus JJ, Rich SS, Warram JH et al. Aldose reductase gene polymorphisms and susceptibility to diabetic nephropathy in Type 1 diabetes mellitus. Diabet Med 2000; 17: 111-118.
30. Liu YF, Wat NM, Chung SS, Ko BC, Lam KS. Diabetic nephropathy is associated with the 5′-end dinucleotide repeat polymorphism of the aldose reductase gene in Chinese subjects with Type 2 diabetes. Diabet Med 2002; 19: 113-118.
31. Kao YL, Donaghue K, Chan A, Knight J, Silink M. A novel polymorphism in the aldose reductase gene promoter region is strongly associated with diabetic retinopathy in adolescents with type 1 diabetes. Diabetes 1999; 48: 1338-1340.
32. Demaine A, Cross D, Millward A. Polymorphisms of the aldose reductase gene and susceptibility to retinopathy in type 1 diabetes mellitus. Invest Ophthalmol Vis Sci 2000; 41: 4064-4068.
33. n dinucleotide repeat polymorphic marker at the 5′-region of the aldose reductase gene with retinopathy but not with nephropathy or neuropathy in Japanese patients with Type 2 diabetes mellitus. Diabet Med 1999; 16: 744-748.
34. Olmos P, Futers S, Acosta AM, Siegel S, Maiz A, Schiaffino R et al. (AC)23 [Z-2] polymorphism of the aldose reductase gene and fast progression of retinopathy in Chilean type 2 diabetics. Diabetes Res Clin Pract 2000; 47: 169-176.
35. Kumaramanickavel G, Sripriya S, Ramprasad VL, Upadyay NK, Paul PG, Sharma T. Z-2 aldose reductase allele and diabetic retinopathy in India. Ophthalmic Genet 2003; 24: 41-48.
36. Heesom AE, Millward A, Demaine AG. Susceptibility to diabetic neuropathy in patients with insulin dependent diabetes mellitus is associated with a polymorphism at the 5′ end of the aldose reductase gene. J Neurol Neurosurg Psychiatry 1998; 64: 213-216.
37. Dyer PH, Chowdhury TA, Dronsfield MJ, Dunger D, Barnett AH, Bain SC. The 5′-end polymorphism of the aldose reductase gene is not associated with diabetic nephropathy in Caucasian type I diabetic patients. Diabetologia 1999; 42: 1030-1031.
38. Moczulski DK, Burak W, Doria A, Zychma M, Zukowska-Szczechowska E, Warram JH et al. The role of aldose reductase gene in the susceptibility to diabetic nephropathy in Type II (non-insulin-dependent) diabetes mellitus. Diabetologia 1999; 42: 94-97.
39. Neamat-Allah M, Feeney SA, Savage DA, Maxwell AP, Hanson RL, Knowler WC et al. Analysis of the association between diabetic nephropathy and polymorphisms in the aldose reductase gene in Type 1 and Type 2 diabetes mellitus. Diabet Med 2001; 18: 906-914.
40. Maeda S, Haneda M, Yasuda H, Tachikawa T, Isshiki K, Koya D et al. Diabetic nephropathy is not associated with the dinucleotide repeat polymorphism upstream of the aldose reductase (ALR2) gene but with erythrocyte aldose reductase content in Japanese subjects with type 2 diabetes. Diabetes 1999; 48: 420-422.
41. Ng DP, Conn J, Chung SS, Larkins RG. Aldose reductase (AC)(n) microsatellite polymorphism and diabetic microvascular complications in Caucasian Type 1 diabetes mellitus. Diabetes Res Clin Pract 2001; 52: 21-27.
42. Park HK, Ahn CW, Lee GT, Kim SJ, Song YD, Lim SK et al. (AC)(n) polymorphism of aldose reductase gene and diabetic microvascular complications in type 2 diabetes mellitus. Diabetes Res Clin Pract 2002; 55: 151-157.
43. Hodgkinson AD, Sondergaard KL, Yang B, Cross DF, Millward BA, Demaine AG. Aldose reductase expression is induced by hyperglycemia in diabetic nephropathy. Kidney Int 2001; 60: 211-218.
44. Ohtaka M, Tawata M, Hosaka Y, Onaya T. Glucose modulation of aldose reductase mRNA expression and its activity in cultured calf pulmonary artery endothelial cells. Diabetologia 1992; 35: 730-734.
45. Li Q, Xie P, Huang J, Gu Y, Zeng W, Song H. Polymorphisms and functions of the aldose reductase gene 5′ regulatory region in Chinese patients with type 2 diabetes mellitus. Chin Med J (Engl) 2002; 115: 209-213.
46. Makiishi T, Araki S, Koya D, Maeda S, Kashiwagi A, Haneda M. C-106T polymorphism of AKR1B1 is associated with diabetic nephropathy and erythrocyte aldose reductase content in Japanese subjects with type 2 diabetes mellitus. Am J Kidney Dis 2003; 42: 943-951.
47. Uusitupa M, Siitonen O, Aro A, Pyörälä K. Prevalence of coronary heart disease, left ventricular failure and hypertension in middle-aged, newly diagnosed type 2 (non-insulin-dependent) diabetic subjects. Diabetologia 1985; 28: 22-27.
48. Niskanen L, Karjalainen J, Siitonen O, Uusitupa M. Metabolic evolution of type 2 diabetes: a 10-year follow-up from the time of diagnosis. J Intern Med 1994; 236: 263-270.
49. WHO Expert Committee on Diabetes Mellitus. Second report. World Health Organ Tech Rep Series 1980; 646: 1-80.
50. Thompson EA, Deeb S, Walker D, Motulsky AG. The detection of linkage disequilibrium between closely linked markers: RFLPs at the AI-CIII apolipoprotein genes. Am J Hum Genet 1988; 42: 113-124.
51. Yamamoto T, Sato T, Hosoi M, Yoshioka K, Tanaka S, Tahara H et al. Aldose reductase gene polymorphism is associated with progression of diabetic nephropathy in Japanese patients with type 1 diabetes mellitus. Diabetes Obes Metab 2003; 5: 51-57.
52. Ikegishi Y, Tawata M, Aida K, Onaya T. Z-4 allele upstream of the aldose reductase gene is associated with proliferative retinopathy in Japanese patients with NIDDM, and elevated luciferase gene transcription in vitro. Life Sci 1999; 65: 2061-2070.
53. Bruno G, Biggeri A, Merletti F, Bargero G, Ferrero S, Pagano G et al. Low incidence of end-stage renal disease and chronic renal failure in type 2 diabetes: a 10-year prospective study. Diabetes Care 2003; 26: 2353-2358.
54. Caramori ML, Fioretto P, Mauer M. The need for early predictors of diabetic nephropathy risk: is albumin excretion rate sufficient? Diabetes 2000; 49: 1399-1408.
55. Bowden DW. Genetics of kidney disease. Kidney Int 2003; Suppl.: S8-12.
56. Lee SC, Wang Y, Ko GT, Critchley JA, Ng MC, Tong PC et al. Association of retinopathy with a microsatellite at 5′ end of the aldose reductase gene in Chinese patients with late-onset Type 2 diabetes. Ophthalmic Genet 2001; 22: 63-67.
57. Wang Y, Ng MC, Lee SC, So WY, Tong PC, Cockram CS et al. Phenotypic heterogeneity and associations of two aldose reductase gene polymorphisms with nephropathy and retinopathy in type 2 diabetes. Diabetes Care 2003; 26: 2410-2415.
58. Isermann B, Schmidt S, Bierhaus A, Schiekofer S, Borcea V, Ziegler R et al. (CA)(n) dinucleotide repeat polymorphism at the 5′-end of the aldose reductase gene is not associated with microangiopathy in Caucasians with long-term diabetes mellitus 1. Nephrol Dial Transplant 2000; 15: 918-920.
59. Yang B, Millward A, Demaine A. Functional differences between the susceptibility Z-2/C-106 and protective Z+2/T-106 promoter region polymorphisms of the aldose reductase gene may account for the association with diabetic microvascular complications. Biochim Biophys Acta 2003; 1639: 1-7.
60. Niskanen LK, Penttilä I, Parviainen M, Uusitupa MI. Evolution, risk factors, and prognostic implications of albuminuria in NIDDM. Diabetes Care 1996; 19: 486-493.